Skip to main content
. 2019 Apr 20;4:100015. doi: 10.1016/j.eurox.2019.100015

Table 1.

Study characteristics.

Nelson et al. (17): Kumar et al. (16): Gomez-Lobo et al. (15):
Publication year: 2016 2013 2014
Nation: USA Canada USA
Number of hospitals or centres: Two One Two
Vaccine type: Quadrivalent HPV vaccinea Quadrivalent HPV vaccinea Quadrivalent HPV vaccinea
Methods of measuring: IgG cLIA and cLIA IgG ELISA and cLIA cLIA
Participants: n = 23b n = 47c n = 17d
Sex (n): Females (23) Females (31) Not specified
Males (16)
Age range in years: 11- 21 18 - 35 11-19
Type of organ transplant (n): Kidney (23) Kidney (30) Kidney (14)
Liver (1) Liver (3)
Lung (11)
Heart (3)
Heart-lung / multivisceral (2)

cLIA; competitive Luminex Immunoassay, IgG cLIA; Immunoglobulin G competitive Luminex Immunoassay, IgG ELISA; Immunoglobulin G enzyme-linked immunosorbent assay.

a

The quadrivalent HPV vaccine was given at month 0, month 2 and month 6.

b

Nelson et al.(17) enrolled 67 patients, 57 patients completed the three-dose vaccine series and had at least one blood draw after vaccination. Of these 57 patients; 25 had chronic kidney disease, nine were dialysis patients and 23 were kidney transplant recipients.

c

Kumar et al.(16) enrolled 50 patients, two patients did not receive any doses of the vaccine and one was found to have a prior history of low-grade squamous lesion. These three patients were excluded, while n = 47 continued in the study.

d

Gomez-Lobo et al.(15) enrolled 25 liver and kidney transplant recipients, of these 17 patients fulfilled criteria to start vaccination.